FORMULATION AND EVALUATION OF RIFAMPICIN NANOPARTICLES

Kondoju Shailaja and Jimidi Bhaskar*

Nanoparticles offer innovative solutions for drug delivery and research due to their unique size-dependent properties and potential for new therapeutic developments. They enable controlled and site-specific drug delivery, presenting advantages over traditional vehicles like creams and emulsions, such as controlled release, minimal skin irritation, and active compound protection. However, challenges include drug expulsion from nanoparticles due to the highly ordered crystalline lipid matrix, which restricts drug accommodation. To address this, nanostructured lipid carriers (NLC) were explored. This study focuses on formulating Rifampicin nanoparticles using NLC to enhance stability and targeted delivery. Rifampicin, an antimicrobial agent for mycobacterial and gram-positive infections, was chosen as the model drug. The research evaluates the performance of Rifampicin-loaded NLC in terms of drug release, stability, and efficacy, demonstrating significant improvements in drug delivery systems.